Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

79.67
-2.5400-3.09%
Pre-market: 80.400.7300+0.92%07:33 EDT
Volume:681.07K
Turnover:54.71M
Market Cap:6.55B
PE:-22.47
High:83.41
Open:82.41
Low:79.07
Close:82.21
52wk High:103.00
52wk Low:28.06
Shares:82.26M
Float Shares:54.63M
Volume Ratio:1.64
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5458
EPS(LYR):-3.6900
ROE:-27.09%
ROA:-17.16%
PB:4.26
PE(LYR):-21.59

Loading ...

Kymera COO Jeremy Chadwick disposes 300 shares for $27,000

Reuters
·
Apr 25

Kymera Therapeutics to report first-quarter financial results, host webcast call

Reuters
·
Apr 23

Kymera COO Jeremy Chadwick disposes of USD 589,510 Kymera Therapeutics shares

Reuters
·
Apr 17

Kymera Therapeutics Chief Business Officer Noah Goodman sells 1,347 shares for $121,230

Reuters
·
Apr 17

Kymera director Bruce Booth disposes of common shares worth $836,290.08

Reuters
·
Apr 17

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

FDA grants fast track designation to Kymera Therapeutics KT-621

TIPRANKS
·
Apr 13

Kymera says FDA grants Fast Track designation for KT-621 in eosinophilic asthma

Reuters
·
Apr 13

Kymera Therapeutics Inc - KT-621 Broaden2 Phase 2B Atopic Dermatitis Trial Ongoing, Data Expected by Mid-2027

THOMSON REUTERS
·
Apr 13

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma

THOMSON REUTERS
·
Apr 13

Kymera CBO Noah Goodman disposes of common shares worth $893,260.62

Reuters
·
Apr 11

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

BUZZ-Kymera rises as Gilead pays $45 million for experimental cancer drug

Reuters
·
Apr 09

Kymera Therapeutics Inc - Gilead to Advance KT-200 Into Ind-Enabling Studies for 2027 Ind Filing

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Inc - to Receive $45 Mln Milestone Payment From Gilead for KT-200 Option

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Inc - May Receive Tiered Royalties From High Single-Digit to Mid-Teens on Sales

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Inc - Eligible for up to $750 Mln in Total Payments Under Agreement

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

GlobeNewswire
·
Apr 09

Kymera COO Jeremy G Chadwick disposes of USD 1.9 million common shares

Reuters
·
Apr 02